Imaging PARP with [¹⁸F]rucaparib in pancreatic cancer models.

ABSTRACT:

Purpose

Rucaparib, an FDA-approved PARP inhibitor, is used as a single agent in maintenance therapy to provide promising treatment efficacy with an acceptable safety profile in various types of BRCA-mutated cancers. However, not all patients receive the same benefit from rucaparib-maintenance therapy. A predictive biomarker to help with patient selection for rucaparib treatment and predict clinical benefit is therefore warranted. With this aim, we developed [¹⁸F]rucaparib, an ¹⁸F-labelled isotopologue of rucaparib, and employed it as a PARP-targeting agent for cancer imaging with PET. Here, we report the in vitro and in vivo evaluation of [¹⁸F]rucaparib in human pancreatic cancer models.

Method

We incorporated the positron-emitting ¹⁸

SUBMITTER: Chan CY 

PROVIDER: S-EPMC9399069 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature